tradmap

TELO Financials Telomir Pharmaceuticals, Inc.

4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Revenue & net income
-$17M -$8M $0 2022 2023 2024 2025
RevenueNet income
Margins (gross / operating / net)
0% 50% 100% 2022 2023 2024 2025
GrossOperatingNet
Free cash flow (CFO − capex)
$0 $1 $1 2022 2023 2024 2025
Free cash flow
Cash vs total debt
$0 $633066 $1M 2022 2023 2024 2025
CashTotal debt
Cash flow: operating / investing / financing
-$5M $2M $10M $0 2022 2023 2024 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MFCFTotal debtCash
2025 -$10M
2024 -$17M $1M
2023 -$13M
2022 -$854147

Frequently asked questions

Is TELO growing its revenue and profit?

See the revenue and net-income charts above for Telomir Pharmaceuticals, Inc.'s multi-year trend.

How much debt does TELO have?

As of FY2025, Telomir Pharmaceuticals, Inc. reported — of total debt against — of cash.

What is TELO's profit margin?

In FY2025, gross margin was —, operating margin —, and net margin —.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.